ECB: Sintra signals and sticky hike premium – Commerzbank

Source Fxstreet

Commerzbank’s Guntermann highlights the Sintra forum as a key event for European Central Bank (ECB) communication, with Lagarde’s opening speech and a heavyweight policy panel midweek. Markets have pared ECB hike expectations to about 27 bps by April, but the bank doubts Sintra rhetoric will justify further front-end yield declines, keeping a sticky rate hike premium embedded in pricing.

Sintra forum to shape expectations

"More ECB colour is in store at the Sintra forum (agenda). Lagarde will deliver the opening speech after the dinner tonight. The main market focus will be on Wednesday's heavyweight policy panel featuring Lagarde, Warsh, Bailey and Macklem."

"The market has started to curb ECB rate hike expectations, with only a total of 27bp higher rates priced in by April. However, we doubt that ECB rhetoric will substantiate a further downward correction in front-end yields."

"BIS [Bank for International Settlements] annual report warns of "new fiscal-financial stability nexus and shifting inflation dynamics"."

"Kashkari penciled in one hike this year and rates on hold in 2027, as he is concerned about broader inflationary pressures, with AI probably pushing up market rates. Barkin warns of high inflation but sees signs of relief."

"Search for new leader of Atlanta Fed resumes, allowing Warsh to have a say in the selection of a candidate who will vote in 2027."

(This article was created with the help of an Artificial Intelligence tool and reviewed by an editor.)

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Why the S&P 500’s Path to 9,000 Runs Into Trouble in 2027The boldest S&P 500 forecast on Wall Street sees 9,000 by year-end, roughly 17% above where the index trades now. The fuel is the AI boom and a wall of idle cash.The warning is that the same AI trade
Author  Beincrypto
15 hours ago
The boldest S&P 500 forecast on Wall Street sees 9,000 by year-end, roughly 17% above where the index trades now. The fuel is the AI boom and a wall of idle cash.The warning is that the same AI trade
placeholder
Treasury Just Drew a Line in the Sand at 5.3%, and Bitcoin NoticedThe US Treasury said Wednesday it will at least double the size of its long-end debt buybacks. The 30-year yield reversed sharply from a 19-year high, and Bitcoin climbed past $65,000.The larger opera
Author  Beincrypto
15 hours ago
The US Treasury said Wednesday it will at least double the size of its long-end debt buybacks. The 30-year yield reversed sharply from a 19-year high, and Bitcoin climbed past $65,000.The larger opera
placeholder
Crypto Prices Explode With Surprise Rally: Is the Bull Market Back? Bitcoin (BTC) jumped 5.8% to levels above $69,500 on Wednesday, wiping out $1.23 billion in bets against it in one hour. Is the crypto bull market back?The rally ran market-wide, with Ethereum (ETH) u
Author  Beincrypto
15 hours ago
Bitcoin (BTC) jumped 5.8% to levels above $69,500 on Wednesday, wiping out $1.23 billion in bets against it in one hour. Is the crypto bull market back?The rally ran market-wide, with Ethereum (ETH) u
placeholder
Bitcoin is a “Cheat Code” to Retire Without Selling, Analyst Explains WhyBitcoin functions as a genuine cheat code for retiring without ever selling, according to analyst and entrepreneur Mark Moss, who laid out that thesis in a recent Coin Stories podcast interview.His ce
Author  Beincrypto
15 hours ago
Bitcoin functions as a genuine cheat code for retiring without ever selling, according to analyst and entrepreneur Mark Moss, who laid out that thesis in a recent Coin Stories podcast interview.His ce
placeholder
Eli Lilly Price Forecast: The Next Big Stock After Weight-Loss Drug Breakthrough?Eli Lilly is one of the most popular names today in America’s weight-loss and diabetes drug market. Its drugs delivered an average weight loss of 28.3% in a Phase 3 trial, approaching results historic
Author  Beincrypto
15 hours ago
Eli Lilly is one of the most popular names today in America’s weight-loss and diabetes drug market. Its drugs delivered an average weight loss of 28.3% in a Phase 3 trial, approaching results historic
goTop
quote